Race Oncology Dirección

Dirección controles de criterios 2/4

El CEO de Race Oncology's es Daniel Tillett , nombrado en Nov 2023, tiene una permanencia de menos de un año. compensación anual total es A$835.75K, compuesta por 39.8% salario y 60.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 9.84% de las acciones de la empresa, por valor de A$20.81M. La antigüedad media del equipo directivo y de la junta directiva es de 0.7 años y 3.5 años, respectivamente.

Información clave

Daniel Tillett

Chief Executive Officer (CEO)

AU$835.7k

Compensación total

Porcentaje del salario del CEO	39.8%
Permanencia del CEO	less than a year
Participación del CEO	9.8%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Daniel Tillett en comparación con los beneficios de Race Oncology?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$11m
Jun 30 2023	AU$836k	AU$332k	-AU$10m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$11m
Sep 30 2022	n/a	n/a	-AU$11m
Jun 30 2022	AU$1m	AU$228k	-AU$11m
Mar 31 2022	n/a	n/a	-AU$10m
Dec 31 2021	n/a	n/a	-AU$9m
Sep 30 2021	n/a	n/a	-AU$8m
Jun 30 2021	AU$1m	AU$167k	-AU$6m
Mar 31 2021	n/a	n/a	-AU$5m
Dec 31 2020	n/a	n/a	-AU$4m
Sep 30 2020	n/a	n/a	-AU$4m
Jun 30 2020	AU$147k	n/a	-AU$4m

Compensación vs. Mercado: La compensación total de Daniel($USD539.02K) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD289.12K).

Compensación vs. Ingresos: La compensación de Daniel ha sido consistente con los resultados de la empresa en el último año.

CEO

Daniel Tillett

less than a year

Permanencia

AU$835,747

Compensación

Dr. Daniel Tillett serves as Chief Executive Officer of Race Oncology Limited since November 22, 2023. He served as Non-Executive Director at Simble Solutions Limited since February 16, 2022 until July 03,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel Tillett	Chief Executive Officer	less than a year	AU$835.75k	9.84% A$ 21.4m
Peter Smith	Executive Director	less than a year	AU$635.00	sin datos
Brendan Brown	Chief Financial Officer	less than a year	sin datos	sin datos
Tim Hammond	Interim Chief Scientific Officer	1.1yrs	sin datos	sin datos
Michelle Rashford	Chief Medical Officer	less than a year	sin datos	sin datos
Peter Webse	Company Secretary	7.9yrs	sin datos	sin datos

0.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de RAC no se considera experimentado ( 0.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Smith	Executive Director	less than a year	AU$635.00	sin datos
Martin Tallman	Member of Scientific Advisory Board	7.3yrs	sin datos	sin datos
Phillip Lynch	Non-Executive Director	3.8yrs	AU$715.00k	0.26% A$ 563.2k
Douglas Smith	Member of Scientific Advisory Board	no data	sin datos	sin datos
Roland Walter	Member of Scientific Advisory Board	no data	sin datos	sin datos
Borje Andersson	Chairman of Clinical Advisory Board	4.3yrs	AU$815.36k	sin datos
Jaap-Jan Boelens	Member of Clinical Advisory Board	4.2yrs	sin datos	sin datos
Mary Harney	Independent Non-Executive Chair	3.2yrs	AU$148.56k	0.014% A$ 30.7k
Jianjun Chen	Member of Scientific Advisory Board	3yrs	sin datos	sin datos
James Breitenbucher	Member of Scientific Advisory Board	1.9yrs	sin datos	sin datos

3.5yrs

Permanencia media

Junta con experiencia: La junta directiva de RAC se considera experimentada (3.5 años de antigüedad promedio).

Race Oncology Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Race Oncology Limited Announces Board Changes

Race Oncology Limited Announces Board Changes

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Recent updates

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel

Insider recently sold AU$4.8m worth of stock

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Insider recently sold AU$6.6m worth of stock

Race Oncology Limited Announces Compelling Preclinical Breast Cancer Results

Insider recently sold AU$2.1m worth of stock

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

New 90-day high: AU$3.29

Race Oncology Limited Announces Positive Early Preclinical Ovarian Cancer Results

Professor Borje Andersson to Resign as Chief Medical Officer of Race Oncology Limited

Race Oncology Limited Appoints Mary Harney as Non-Executive Director

New 90-day high: AU$2.48

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Race Oncology Limited Announces Borje Andersson Resigns as an Executive Director

Race Oncology Limited Announces Breast Cancer Clinical Trial Program Initiated

New 90-day high: AU$1.30

Race Oncology Limited Reports Phase II Bisantrene Trial Data to be presented at ASH 2020